Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Aulos Bioscience

Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating the Combination of Avelumab and AU-007 for the Treatment of Non-Small Cell Lung Cancer
From Aulos Bioscience
Via Business Wire
Strong Evidence of AU-007’s Anti-Tumor Activity in Advanced Solid Tumor Cancers Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Aulos Bioscience
Via Business Wire
Aulos Bioscience Presents Phase 2 Dose Selection Data for Novel IL-2 Therapeutic Antibody, AU-007, at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From Aulos Bioscience
Via Business Wire
Aulos Bioscience Announces Presentation Detailing Phase 2 Dose Selection for AU-007 in Solid Tumor Treatment at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
From Aulos Bioscience
Via Business Wire
Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic Antibody, AU-007, at 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Aulos Bioscience
Via Business Wire
Aulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting
From Aulos Bioscience
Via Business Wire
Aulos Bioscience Enters Into Clinical Trial Collaboration and Supply Agreement With Merck KGaA, Darmstadt, Germany To Study Combination of Bavencio® With AU-007
From Aulos Bioscience
Via Business Wire
Aulos Bioscience to Present Updated Phase 1/2 Clinical Trial Results for Novel IL-2 Therapeutic AU-007 in Advanced Solid Tumor Cancers at 2024 ASCO Annual Meeting
From Aulos Bioscience
Via Business Wire
First Patient Dosed in Phase 2 Portion of Aulos Bioscience’s Phase 1/2 Clinical Trial for AU-007, a Computationally Designed IL-2 Antibody for Solid Tumor Cancers
From Aulos Bioscience
Via Business Wire
Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase 1/2 Study Evaluating Computationally Designed IL-2 Antibody for Treatment of Solid Tumors
From Aulos Bioscience
Via Business Wire
New Phase 1 Dose Escalation Data Show Well-Tolerated Safety Profile and Anti-Tumor Activity for Aulos Bioscience’s AU-007 at Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Aulos Bioscience
Via Business Wire
New Phase 1 Dose Escalation Cohorts Data for Aulos Bioscience’s AU-007 Show Favorable Pharmacodynamic Effects at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Aulos Bioscience
Via Business Wire
Aulos Bioscience to Present Encouraging Pharmacodynamic Data for AU-007 From Phase 1 Dose Escalation Cohorts at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Aulos Bioscience
Via Business Wire
Aulos Bioscience Announces Presentation of Updated Safety and Efficacy Data From First-in-Human Phase 1/2 Clinical Trial of AU-007 at 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Aulos Bioscience
Via Business Wire
Aulos Bioscience Raises $20 Million in Series A Extension Financing From Apple Tree Partners
From Aulos Bioscience
Via Business Wire
Interim Results From Phase 1/2 Clinical Trial in Solid Tumor Cancers Demonstrate Aulos Bioscience’s AU-007 is Well Tolerated and Uniquely Reduces Regulatory T Cells
From Aulos Bioscience
Via Business Wire
First U.S. Patient Dosed in Aulos Bioscience’s Phase 1/2 Clinical Trial of AU-007, a Novel IL-2 Therapeutic for the Treatment of Solid Tumors
From Aulos Bioscience
Via Business Wire
Aulos Bioscience Presents Initial Data From First-in-Human Phase 1/2 Clinical Trial of Computationally Designed Antibody AU-007 at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Aulos Bioscience
Via Business Wire
Aulos Bioscience Announces FDA Clearance of IND Application for AU-007, a Novel Immunotherapy for the Treatment of Solid Tumors
From Aulos Bioscience
Via Business Wire
Aulos Bioscience to Present Initial Safety Data From First-in-Human Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Aulos Bioscience
Via Business Wire
Aulos Bioscience Presents Poster on Phase 1/2 Clinical Trial of Computationally Designed IL-2 Antibody AU-007 at 2022 ASCO Annual Meeting
From Aulos Bioscience
Via Business Wire
Aulos Bioscience Initiates Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 for the Treatment of Solid Tumors
From Aulos Bioscience
Via Business Wire
Aulos Bioscience Announces Presentation on First-in-Human Phase 1/2 Clinical Trial of Novel IL-2 Therapeutic AU-007 at 2022 ASCO Annual Meeting
From Aulos Bioscience
Via Business Wire
Aulos Bioscience Announces Preclinical Data Demonstrating Ability of Novel IL-2 Therapeutic AU-007 to Eliminate Solid Tumors
From Aulos Bioscience
Via Business Wire
Aulos Bioscience Receives HREC Approval to Initiate First-in-Human Clinical Trial Evaluating Anti-Tumor Activity of Novel IL-2 Therapeutic AU-007
From Aulos Bioscience
Via Business Wire
Aulos Bioscience Presents Preclinical Data Demonstrating Anti-Tumor Activity of AU-007, a Novel IL-2 Therapeutic, at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Aulos Bioscience
Via Business Wire
Aulos Bioscience to Present New Preclinical Data on Computationally Evolved IL-2 Human Antibody AU-007 at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting
From Aulos Bioscience
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.